Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease. Edinburgh Artery Study

European Heart Journal

Volumn 20, Issue 5, 1999, Pages 344-353

  Price, J F ^a   Mowbray, P I ^a   Lee, A J ^a   Rumley, A ^b   Lowe, G D O ^b   Fowkes, F G R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Corollary artery disease; Peripheral arterial disease; Risk factors; Smoking

Indexed keywords

ANTIOXIDANT; FIBRIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE; BLOOD VISCOSITY; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; ENDOTHELIUM; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; VITAMIN INTAKE;

AGED; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD VISCOSITY; CHOLESTEROL; CORONARY DISEASE; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SMOKING;

EID: 0032961577     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1194     Document Type: Article

References (60)

1. Heliovaara M, Karvonen MJ, Vilhunen R, Punsar S. Smoking, carbon monoxide and atherosclerotic diseases. Br Med J. 1:1978;268-270.
2. Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. Br Med J. 1:1978;1379-1381.
3. Doll R, Grey R, Hafner B, Peto R. Mortality in relation to smoking: 20 years' observation on female British doctors. Br Med J. 2:1980;967-971.
4. Doll R, Peto R. Mortality in relation to smoking: 20 years' observation on male British doctors. Br Med J. 2:1976;1525-1536.
5. Blann AD. Increased circulating levels of von Willebrand factor antigen in smokers may be due to lipid peroxides. Med Sci Res. 19:1991;535-536.
6. Smith FB, Lowe GDO, Fowkes FGR. Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial diseases. Atherosclerosis. 102:1993;155-162.
7. Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet. ii:1987;986-988.
8. Ogston D, Bennett NB, Ogston CM. The influence of cigarette smoking on the plasma fibrinogen concentrations. Atherosclerosis. 11:1970;349-352.
9. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid lipoprotein concentrations: an analysis of published data. Br Med J. 298:1989;784-788.
10. Duthie GG, Arthur JR, James PT. Effects of smoking and vitamin E on blood anti-oxidant status. Am J Clin Nutr. 40:1990;273-287.
11. Fowkes FGR, Housley E, Cawood EHH, MacIntyre CCA, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 20:1991;384-391.
12. Department of Health and Social Security, Office of Population Censuses and Surveys. Classification of Occupation and Coding Index, London, England, Her Majesty's Stationery Office, 1980.
13. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudiction in field surveys. Bull WHO. 27:1962;645-658.
14. Yarnell JWG, Fehily AM, Milbank JE, Sweetnam PM, Walker CL. A short dietary questionnaire for use in a epidemiological survey: comparison with weighted dietary records. Hum Nutr: Appl Nutr. 37A:1983;103-112.
15. Plant MA, Peck DF, Stuart R. Self reported drinking habits and alcohol related consequences among a cohort of Scottish teenagers. Br J Addict. 77:1982;75-90.
16. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code manual of electrocardiographic findings: Standards and procedures for measurement and classification. 1982;John Wright, London.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 18:1972;499-502.
18. Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation. 87:1993;1915-1920.
19. Leng GC, Lee AJ, Fowkes FGR. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 25:1996;1172-1181.
20. Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J. 108:1984;150-158.
21. Leng GC, Lee AJ, Fowkes FGR, Lowe GDO, Housley E. The relationship between cigarette smoking and cardiovascular disease in peripheral arterial disease compared with ischaemic heart disease. The Edinburgh Artery Study. Eur Heart J. 16:1995;1542-1548.
22. Fowkes FGR, Housley E, Riemersma RA. Smoking, lipids, glucose intolerance and blood pressure for risk factors for peripheral atherosclerosis compared with ischaemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 135:1992;331-340.
23. Fowkes FGR. Aetiology of peripheral atherosclerosis: smoking seems especially important. Br Med J. 298:1989;405-406.
24. Powell JT. Smoking. Epidemiology of Peripheral Vascular Disease. 1991;Springer-Verlag, Berlin. p. 141-53.
25. Woodward M, Tunstall-Pedoe H. An iterative technique for identifying smoking deceivers with application to the Scottish Heart Health Study. Prev Med. 21:1992;88-97.
26. Criqui MH, Cowan LD, Tyroler HA. Lipoproteins as mediators for the effects of alcohol consumption and cigarette smoking on cardiovascular mortality: results from the Lipid Research Clinics Follow-up Study. Am J Epidemiol. 126:1987;629-637.
27. Miller NE, Hammett F, Saltissi S. Relation of angio-graphically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J. 282:1981;1741-1744.
28. Ballantyne FC, Clark RS, Simpson HS. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metabolism. 31:1982;433-437.
29. Haffner S, Appelbaum-Bowden D, Wahl PW. Epidemiological correlates of high density lipoprotein subfractions, apolipoproteins A-I, A-II, and D, and lecithin cholesterol acyltranferase. Effects of smoking, alcohol, and adiposity. Arteriosclerosis. 5:1985;169-177.
30. Rimm EB, Giovannucci EL, Willett WC. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet. 338:1991;464-468.
31. Midgette AS, Baron JA, Rohan TE. Do cigarette smokers have diets that increase their risks of coronary heart disease and cancer. Am J Epidemiol. 137:1993;521-529.
32. Fehily AM, Phillips KM, Yarnell JWG. Diet, smoking, social class and body mass index in the Caerphilly Heart Disease Study. Am J Cli Nutr. 40:1984;827-833.
33. Gordon T, Kannel WB, Dawber TR, McGee D. Changes associated with quitting cigarette smoking: The Framingham Study. Am Heart J. 90:1975;322-328.
34. Cummins RO, Shaper AG, Walker M, Wale CJ. Smoking and drinking by middle-aged British men: effects of social class and town of residence. Br Med J. 283:1981;1497-1502.
35. Bolton-Smith C, Casey CE, Gey KF, Smith WCS, Tunstall-Pedoe H. Antioxidant vitamin intakes assessed using a food frequency questionnaire: correlation with biochemical status in smokers and non-smokers. Br J Nutr. 65:1991;337-346.
36. Scheffler E, Wiest E, Woehrle J. Smoking influences the atherogenic potential of low-density lipoprotein. Clin Invest. 70:1992;263-268.
37. Margetts BM, Jackson AA. Interactions between people's diets and their smoking habits: the dietary and nutritional survey of British adults. Br Med J. 307:1993;1381-1384.
38. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J. 113:1987;1006-1010.
39. Nicoloso G, Hauert J, Kruithof EKO, van Melle G, Bachmann F. Fibrinolysis in normal subjects: comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemost. 59:1988;299-303.
40. Nilsson TK. Analysis of factors affecting tissue plasminogen activator activity and antigen concentrations before and after venous occlusion in 123 subjects. Clin Chem Enzymol Commun. 1:1989;335-341.
41. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 332:1995;635-641.
42. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary heart disease. Circulation. 88:1993;2030-2034.
43. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 341:1993;1165-1168.
44. van der Bom JG, de Knijff P, Haverkate F. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. Circulation. 95:1997;2623-2627.
45. Fowkes FGR, Lowe GDO, Housley E. Cross-linked fibrin degradation products, progression of peripheral arterial disease and risk of coronary artery disease. Lancet. 342:1992;84-86.
46. Lowe GDO, Rumley A, Yarnell JWG, Sweetnam PM, Thomas HF. Fibrin D-dimer, von Willebrand factor and tissue plasminogen activator antigens are predictors of major ischaemic heart disease: the Caerphilly Study. Blood Coag Fibrinolysis. 6:1995;156-157.
47. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol. 88:1994;601-604.
48. Lee AJ, Fowkes FGR, Rattray A, Rumley A, Lowe GDO. Haemostatic and rheological factors in intermittent claudi-cation: the influence of smoking and extent of arterial disease. Br J Haematol. 92:1996;226-230.
49. Lowe GDO. Blood viscosity and cardiovascular disease. Thromb Haemost. 67:1992;494-498.
50. Ernst E, Matrai A, Schmolzl C, Magyarosy I. Dose effect relationship between smoking and blood rheology. Br J Haematol. 65:1987;485-487.
51. Khosla T, Lowe CR. Obesity and smoking habits. Br Med J. 4:1971;10-13.
52. Jacobs DR, Gottenburg S. Smoking and weight. The Minnesota lipid research clinic. Am J Public Health. 71:1981;391-396.
53. Nemery B, Moavero NE, Brassew L, Stanescu DC. Smoking, lung function and body weight. Br Med J. 286:1983;249-251.
54. Green MS, Jucha E, Luz Y. Blood pressure in smokers and nonsmokers: epidemiologic findings. Am Heart J. 11:1986;932-940.
55. Seltzer CC. Effect of smoking on blood pressure. Am Heart J. 87:1974;558-564.
56. Facchini FS, Hollenbeck CB, Jeppeson J, Chen Y-D, Chen Y-D, Reaven GM. Insulin resistance and cigarette smoking. Lancet. 339:1992;1128-1130.
57. Krupski WC. The peripheral vascular consequences of smoking. Ann Vasc Surg. 5:1991;291-304.
58. Lassila R, Seyberth HW, Haapanen A, Schweer H, Koskenvuo M, Laustiola KE. Vasoactive and atherogenic effects of cigarette smoking: a study of monozygotic twins discordant for smoking. Br Med J. 297:1988;955-957.
59. Corre F, Lellouch J, Schwartz D. Smoking and leucocyte counts. Results of an epidemiological survey. Lancet. 2:1971;632-634.
60. Friedeman GD, Siegelaub AB, Seltzer CC, Feldman R, Collen MF. Smoking habits and the leukocyte count. Arch Environ Health. 26:1973;137-143.